Compare MARA & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MARA | BLTE |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.0B |
| IPO Year | 2010 | 2021 |
| Metric | MARA | BLTE |
|---|---|---|
| Price | $11.34 | $184.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $17.85 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 46.4M | 145.5K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $907,093,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.31 | $492.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 38.20 | N/A |
| 52 Week Low | $6.66 | $65.00 |
| 52 Week High | $23.45 | $200.00 |
| Indicator | MARA | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 59.75 |
| Support Level | $10.28 | $167.80 |
| Resistance Level | $12.51 | $172.02 |
| Average True Range (ATR) | 0.93 | 6.29 |
| MACD | 0.13 | -0.15 |
| Stochastic Oscillator | 72.69 | 91.17 |
MARA Holdings Inc leverages digital asset computing to support the energy transformation. It secures the blockchain ledger and supports the energy transformation by converting clean, stranded, or underutilized energy into economic value. The company also offers technology solutions to optimize data center operations, including next-generation liquid immersion cooling and firmware for Bitcoin miners. It is focused on computing for, acquiring, and holding digital assets as a long-term investment.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.